This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Comuzzi, B. Articles by Culig, Z. Search for Related Content PubMed PubMed Citation Articles by Comuzzi, B. Articles by Culig, Z.

(American Journal of Pathology. 2003;162:233-241.)
© 2003 American Society for Investigative Pathology

Regular Articles

The Transcriptional Co-Activator cAMP Response Element-Binding Protein-Binding Protein Is Expressed in Prostate Cancer and Enhances Androgen- and Anti-Androgen-Induced Androgen Receptor Function

Barbara Comuzzi^*, Leonidas Lambrinidis^*, Hermann Rogatsch, Sonia Godoy-Tundidor^*, Nikola Knezevic, Ivan Krhen, Zvonimir Marekovic, Georg Bartsch^*, Helmut Klocker^*, Alfred Hobisch^* and Zoran Culig^*

From the Departments of Urology^* and Pathology, University of Innsbruck, Innsbruck, Austria; the Department of Urology, General Hospital Feldkirch, Feldkirch, Austria; and the Department of Urology, University of Zagreb, Zagreb, Croatia

Progression of human prostate cancer toward therapy resistance occurs in the presence of wild-type or mutated androgen receptors (ARs) that, in some cases, exhibit aberrant activation by various steroid hormones and anti-androgens. The AR associates with a number of co-activators that possess histone acetylase activity and act as bridging molecules to components of the transcription initiation complex. In previous reports, it was shown that the transcriptional co-activator CREB (cAMP response element-binding protein)-binding protein (CBP) enhances AR activity in a ligand-dependent manner. In the present study, we have investigated whether CBP modifies antagonist/agonist balance of the nonsteroidal anti-androgens hydroxyflutamide and bicalutamide. In prostate cancer DU-145 cells, which were transiently transfected with CBP cDNA, hydroxyflutamide enhanced AR activity to a greater extent than bicalutamide in the presence of either wild-type or the mutated AR 730 valmet. In two sublines of LNCaP cells that contain the mutated AR 877 thrala and overexpressed CBP, increase in AR activity was observed after treatment with hydroxyflutamide but not with bicalutamide. Anti-androgens did not influence AR expression in cells transfected with CBP cDNA, as judged by Western blot analysis. Endogenous CBP protein was detected by Western blot in nuclear extracts from the three prostate cancer cell lines, LNCaP, PC-3, and DU-145, all derived from therapy-resistant prostate cancer. In addition, CBP was expressed in both basal and secretory cells of benign prostate epithelium, high-grade prostate intraepithelial neoplasia, and prostate cancer clinical specimens, as evidenced by immunohistochemical staining. Taken together, our findings demonstrate the selective enhancement of agonistic action of the anti-androgen hydroxyflutamide by the transcriptional co-activator CBP, which is a new, potentially relevant mechanism contributing to the acquisition of therapy resistance in prostate cancer.

This article has been cited by other articles:

				I. Bellezza, H. Neuwirt, C. Nemes, I. T. Cavarretta, M. Puhr, H. Steiner, A. Minelli, G. Bartsch, F. Offner, A. Hobisch, et al. Suppressor of Cytokine Signaling-3 Antagonizes cAMP Effects on Proliferation and Apoptosis and Is Expressed in Human Prostate Cancer Am. J. Pathol., December 1, 2006; 169(6): 2199 - 2208. [Abstract] [Full Text] [PDF]

				K. J. Pienta and D. Bradley Mechanisms underlying the development of androgen-independent prostate cancer. Clin. Cancer Res., March 15, 2006; 12(6): 1665 - 1671. [Full Text] [PDF]

				O. Y. Khan, G. Fu, A. Ismail, S. Srinivasan, X. Cao, Y. Tu, S. Lu, and Z. Nawaz Multifunction Steroid Receptor Coactivator, E6-Associated Protein, Is Involved in Development of the Prostate Gland Mol. Endocrinol., March 1, 2006; 20(3): 544 - 559. [Abstract] [Full Text] [PDF]

				R. Ilagan, L. J. Zhang, J. Pottratz, K. Le, S. Salas, M. Iyer, L. Wu, S. S. Gambhir, and M. Carey Imaging androgen receptor function during flutamide treatment in the LAPC9 xenograft model Mol. Cancer Ther., November 1, 2005; 4(11): 1662 - 1669. [Abstract] [Full Text] [PDF]

				Z Culig, H Steiner, G Bartsch, and A Hobisch Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours Endocr. Relat. Cancer, June 1, 2005; 12(2): 229 - 244. [Abstract] [Full Text] [PDF]

				C. A. Heinlein and C. Chang Androgen Receptor in Prostate Cancer Endocr. Rev., April 1, 2004; 25(2): 276 - 308. [Abstract] [Full Text] [PDF]

				M. J. Linja, K. P. Porkka, Z. Kang, K. J. Savinainen, O. A. Janne, T. L. J. Tammela, R. L. Vessella, J. J. Palvimo, and T. Visakorpi Expression of Androgen Receptor Coregulators in Prostate Cancer Clin. Cancer Res., February 1, 2004; 10(3): 1032 - 1040. [Abstract] [Full Text] [PDF]

				J. D. Debes, T. J. Sebo, C. M. Lohse, L. M. Murphy, D. A. L. Haugen, and D. J. Tindall p300 in Prostate Cancer Proliferation and Progression Cancer Res., November 15, 2003; 63(22): 7638 - 7640. [Abstract] [Full Text] [PDF]